TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03203863

Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric measures of fatness
Description: The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
Study: NCT00086268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03522623

Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study: NCT00502411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
Study: NCT02594995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBP
Study: NCT02156271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02069275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Description: Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two hours bedrest
Description: Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
Study: NCT04209985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Brief telephonic intervention consisting of up to five phone calls from a health coach
Study: NCT01075308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor SB939
Description: SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
Study: NCT01774656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological Treatment
Description: The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
Study: NCT01862692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby-Net
Description: Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Awareness Skills
Description: Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
Study: NCT04271618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTogs Orthotic Undergarment
Description: Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TheraTogs Orthotic Undergarment
Description: Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
Study: NCT00906737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-bot
Description: The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional focused ankle therapy
Description: Conventional focused ankle therapy will be performed by a physical therapist.
Study: NCT00949494

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Synvisc
Description: intra-articular, 3 weekly injections

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc
Description: intra-articular, 3 weekly injections
Study: NCT02880956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: ABBV-8E12 solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: ABBV-8E12 solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: ABBV-8E12 solution for IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ABBV-8E12
Description: placebo solution for intravenous (IV) infusion
Study: NCT00620932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
Study: NCT01661842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional plus UC-MSC treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Study: NCT02495727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-training
Description: Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise snacking
Description: Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
Study: NCT01661842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus placebo treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
Study: NCT02906982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum health formulation in intra-oral device
Description: The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum health formulation on toothbrush
Description: The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
Study: NCT03201081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme
Description: The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
Study: NCT02836639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 0.8 mg/kg four times per day from day -7 to day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 400 mg/m2 from day -5 to day -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 200 mg/m2 starting dose on day -3 and -2
Study: NCT01705847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9820
Description: GS-9820 tablets containing 200 mg of GS-9820 administered orally
Study: NCT01139008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole 1% gel
Description: Apply topically on one side of the face once daily for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: Apply topically on the opposite side of the face twice daily for three weeks
Study: NCT02102711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A oral drops
Study: NCT03924557

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genotype-guided Supportive Care
Description: In this arm, supportive care will be administered based on the results of the genotype test.
Study: NCT03667898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block using NTT
Description: An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar plexus block without NTT
Description: An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
Study: NCT01601600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BYM338 Placebo
Study: NCT01473368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 500 mg, 2 times daily for 14 days
Study: NCT01670994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
Study: NCT01473368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 500 mg, 2 times daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: 875/125 mg 2 times daily at least 1 hour before meals for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: 875/125 mg 2 times daily at least 1 hour before meals for 7 days
Study: NCT03645343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator
Description: This appliance is constructed in one piece to guide the position of the mandible on closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Block
Description: This appliance is constructed in two pieces to guide the position of the mandible on closure
Study: NCT03348189

Intervention type: OTHER
Intervention: Pulse Oximeter
Description: Pulse Oximeter
Study: NCT03496714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation on trauma reactions
Description: The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation on trauma reactions
Description: The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation on safety behaviors
Description: The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
Study: NCT01262183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRT + Panitumumab
Description: Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy without panitumumab
Description: Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
Study: NCT02730156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Altitude exposure
Study: NCT02775929

Intervention type: DRUG
Group type: OTHER
Intervention: FTC-TDF PrEP
Description: FTC-TDF PrEP for HIV-1 uninfected partners

Intervention type: DRUG
Group type: OTHER
Intervention: ART
Description: ART for HIV-1 infected partners
Study: NCT02903459

Intervention type: OTHER
Intervention: Transversal Study so there is no intervention

Intervention type: OTHER
Intervention: Transversal Study so there is no intervention

Intervention type: OTHER
Intervention: Transversal Study so there is no intervention

Intervention type: OTHER
Intervention: Transversal Study so there is no intervention
Study: NCT02465554

Intervention type: PROCEDURE
Intervention: Myocardial contrast echocardiography
Description: Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.

Intervention type: PROCEDURE
Intervention: Myocardial contrast echocardiography
Description: Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
Study: NCT01062373

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of lactating mothers who has delivered prematurely with DHA
Description: Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of lactating mothers who has delivered prematurely with DHA
Description: Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
Study: NCT02889744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Sun
Description: Targeted temperature management for 24 hours with core temperature 36℃ or 33℃

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Sun
Description: Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
Study: NCT04249232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide 80 micrograms per Pen dose
Description: prefilled injector pen to deliver 80 micrograms daily subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo prefilled injector pen
Description: prefilled injector pen to deliver inactive solution daily subcutaneously
Study: NCT03074019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylooligosaccacharide
Description: XOS95 powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylooligosaccacharide
Description: XOS95 powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin powder
Study: NCT00927004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Description: 60 mg, daily dose, oral delivery, 14 days duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Daily dose (1 pill), oral delivery, 14 days
Study: NCT03029988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept (Technetium Tc 99m tilmanocept Injection)
Description: Drug: Technetium Tc 99m tilmanocept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept (Technetium Tc 99m tilmanocept Injection)
Description: Drug: Technetium Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT Imaging
Description: 4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT Imaging
Description: 4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
Study: NCT04787419

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saccharum lactis

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
Study: NCT03736915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection using 1 cc of NaCl 0.9%
Description: The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection using 1 cc of NaCl 0.9%
Description: The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection using 1 cc of NaCl 0.9%
Description: The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Question
Description: Patient is asked at the end of each injection which injection they prefer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Question
Description: Patient is asked at the end of each injection which injection they prefer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Question
Description: Patient is asked at the end of each injection which injection they prefer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient is asked to answer questionairres at the end of each injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient is asked to answer questionairres at the end of each injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient is asked to answer questionairres at the end of each injection
Study: NCT03504176

Intervention type: OTHER
Intervention: Ventilation bundle
Description: ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
Study: NCT01112449

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active medication

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: 200 µg/day of selenomethionine (SM)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose selenized-yeast
Description: 200 µg/day of SY

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose selenized-yeast
Description: 285 µg/day of SY
Study: NCT05003297

Intervention type: OTHER
Intervention: hemogram inflammatory parameters
Description: Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)

Intervention type: OTHER
Intervention: hemogram inflammatory parameters
Description: Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
Study: NCT01502215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary